Literature DB >> 2832239

Transcatheter arterial chemo-embolization for humoral hypercalcemia of hepatocellular carcinoma.

K Suzuki1, N Kono, A Ono, Y Osuga, H Kiyokawa, I Mineo, Y Matsuda, S Miyoshi, S Kawata, Y Minami.   

Abstract

A 50-year-old male with unresectable hepatocellular carcinoma (HCC) had a hypercalcemic crisis with a serum calcium concentration of 7.8 mEq/zeta, without any evidence for bone metastases or parathyroid lesions. The hypercalcemia was thought to be due to increased renal reabsorption of calcium and increased bone resorption, which was probably caused by humoral factors derived from the HCC, some being parathyroid hormone-like factors. Since conservative therapy for hypercalcemia was not sufficiently effective and was accompanied by progressive exacerbation of ascites and leg edema, transcatheter arterial chemo-embolization (TACE) was performed. On the following day, serum calcium concentration decreased from 6.3 mEq/zeta to the normal range, although serum alpha-fetoprotein levels decreased only slightly. Thereafter hypercalcemia did not develop for about 4 weeks. The results demonstrated that TACE can be effective for humoral hypercalcemia of HCC.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2832239     DOI: 10.1007/BF02918853

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  21 in total

1.  A sensitive, precise, and convenient method for determination of 1,25-dihydroxyvitamin D in human plasma.

Authors:  J A Eisman; A J Hamstra; B E Kream; H F DeLuca
Journal:  Arch Biochem Biophys       Date:  1976-09       Impact factor: 4.013

2.  Emergency hepatic arterial embolization for secondary hypercalcemia in hepatocellular carcinoma.

Authors:  A Roche; D Franco; D Dhumeaux; H Bismuth; D Doyon
Journal:  Radiology       Date:  1979-11       Impact factor: 11.105

3.  Relation between serum and urinary calcium with particular reference to parathyroid activity.

Authors:  M Peacock; W G Robertson; B E Nordin
Journal:  Lancet       Date:  1969-02-22       Impact factor: 79.321

4.  Urinary and nephrogenous adenosine 3',5'-monophosphate in the hypercalcemia of malignancy.

Authors:  R K Rude; C F Sharp; R S Fredericks; S B Oldham; N Elbaum; J Link; L Irwin; F R Singer
Journal:  J Clin Endocrinol Metab       Date:  1981-04       Impact factor: 5.958

5.  Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups.

Authors:  A F Stewart; R Horst; L J Deftos; E C Cadman; R Lang; A E Broadus
Journal:  N Engl J Med       Date:  1980-12-11       Impact factor: 91.245

6.  Normalization of hypercalcemia associated with a decrease in renal calcium reabsorption in Leydig cell tumor-bearing rats treated with WR-2721.

Authors:  S Hirschel-Scholz; J Caverzasio; R Rizzoli; J P Bonjour
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

7.  Sclerosing hepatic carcinoma: relationship to hypercalcemia.

Authors:  M Omata; R L Peters; D Tatter
Journal:  Liver       Date:  1981-03

8.  Nephrogenous cyclic adenosine monophosphate as a parathyroid function test.

Authors:  A E Broadus; J E Mahaffey; F C Bartter; R M Neer
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

9.  Diagnostic utility of C-terminal parathyrin measurement as compared with measurements of N-terminal parathyrin and calcium in serum.

Authors:  M Simon; J Cuan
Journal:  Clin Chem       Date:  1980-11       Impact factor: 8.327

10.  Hypercalcemia in glucocorticoid withdrawal.

Authors:  K Suzuki; K Nonaka; K Ichihara; Y Fukumoto; A Miyazaki; Y Yamada; Y Itoh; Y Seino; K Moriwaki; S Tarui
Journal:  Endocrinol Jpn       Date:  1986-04
View more
  4 in total

1.  Embolization of liver tumors: Past, present and future.

Authors:  Ashwin Rammohan; Jeswanth Sathyanesan; Sukumar Ramaswami; Anand Lakshmanan; Perumal Senthil-Kumar; Ulagendra Perumal Srinivasan; Ravi Ramasamy; Palaniappan Ravichandran
Journal:  World J Radiol       Date:  2012-09-28

Review 2.  p53 gene in treatment of hepatic carcinoma: status quo.

Authors:  Yong-Song Guan; Zi La; Lin Yang; Qing He; Ping Li
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

3.  Identification and characterization of a novel small-molecule inhibitor of β-catenin signaling.

Authors:  Evan R Delgado; Jing Yang; Juhoon So; Stephanie Leimgruber; Michael Kahn; Tohru Ishitani; Donghun Shin; Gabriela Mustata Wilson; Satdarshan P Monga
Journal:  Am J Pathol       Date:  2014-05-10       Impact factor: 4.307

4.  The effect of lipiodol deposition in HCC after TACE on the necrosis range of PMCT.

Authors:  HongLiang Sun; JiaYan Ni; XiongYing Jiang; Dong Chen; YaoTing Chen; LinFeng Xu
Journal:  Onco Targets Ther       Date:  2017-08-01       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.